AUTHOR=Zhang Jieting , Chen Jiaxin , Xu Jing , Xue Cheng , Mao Zhiguo 

TITLE=Plant-derived compounds for treating autosomal dominant polycystic kidney disease

JOURNAL=Frontiers in Nephrology

VOLUME=3

YEAR=2023

URL=https://www.frontiersin.org/journals/nephrology/articles/10.3389/fneph.2023.1071441

DOI=10.3389/fneph.2023.1071441

ISSN=2813-0626

ABSTRACT=<p>Autosomal dominant polycystic kidney disease (ADPKD), the most common monogenic hereditary kidney disease, is the fourth leading cause of end-stage kidney disease worldwide. In recent years, significant progress has been made in delaying ADPKD progression with different kinds of chemical drugs, such as tolvaptan, rapamycin, and somatostatin. Meanwhile, numerous plant-derived compounds have been investigated for their beneficial effects on slowing ADPKD progression. Among them, saikosaponin-d, <italic>Ganoderma</italic> triterpenes, curcumin, ginkgolide B, steviol, resveratrol, <italic>Sparganum stoloniferum</italic> Buch.-Ham, <italic>Cordyceps sinensis</italic>, triptolide, quercitrin, naringin, cardamonin, gambogic acid, and olive leaf extract have been found to retard renal cyst development by inhibiting cell proliferation or promoting cell apoptosis in renal cyst-lining epithelial cells. Metformin, a synthesized compound derived from French lilac or goat’s rue (<italic>Galega officinalis</italic>), has been proven to retard the progression of ADPKD. This review focuses on the roles and mechanisms of plant-derived compounds in treating ADPKD, which may constitute promising new therapeutics in the future.</p>